Skip to main content
Erschienen in: Pituitary 2/2009

01.06.2009

Alterations in body composition in acromegaly

verfasst von: Laurence Katznelson

Erschienen in: Pituitary | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Acromegaly is a condition characterized by growth hormone (GH) and insulin-like growth factor-1 (IGF-1) hypersecretion, and is associated with boney overgrowth, and soft tissue abnormalities due to anabolic, lipolytic, and sodium retaining actions of GH. GH and IGF-1 excess is associated with alterations in body composition, including an increase in body water and lean body mass, and a reduction in body fat. Achievement of biochemical control of the disease results in a reduction in body water and fat-free mass, and an increase in body fat. BMD is generally increased in acromegaly, though the anabolic effect of GH excess on bone is reduced, if not negated, by the presence of hypogonadism, particularly with regard to the trabecular compartment. Further studies are necessary to determine the effect of long-term biochemical control on bone density in subjects with acromegaly.
Literatur
1.
Zurück zum Zitat Bengtsson BA, Brummer RJ, Eden S, Bosaeus I (1989) Body composition in acromegaly. Clin Endocrinol (Oxf) 30:121–130 MedlineCrossRef Bengtsson BA, Brummer RJ, Eden S, Bosaeus I (1989) Body composition in acromegaly. Clin Endocrinol (Oxf) 30:121–130 MedlineCrossRef
2.
Zurück zum Zitat Gibney J, Wolthers T, Burt MG, Leung KC, Umpleby AM, Ho KK (2007) Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 92:1479–1484 Medline. doi:10.1210/jc.2006-0664 PubMedCrossRef Gibney J, Wolthers T, Burt MG, Leung KC, Umpleby AM, Ho KK (2007) Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 92:1479–1484 Medline. doi:10.​1210/​jc.​2006-0664 PubMedCrossRef
4.
Zurück zum Zitat Rau H, Fischer H, Schmidt K, Lembcke B, Althoff PH (1991) Effect of bromocriptine withdrawal in acromegaly on body composition as assessed by bioelectrical impedance analysis. Acta Endocrinol (Copenh) 125:273–279 Medline Rau H, Fischer H, Schmidt K, Lembcke B, Althoff PH (1991) Effect of bromocriptine withdrawal in acromegaly on body composition as assessed by bioelectrical impedance analysis. Acta Endocrinol (Copenh) 125:273–279 Medline
6.
7.
Zurück zum Zitat Hansen TB, Gram J, Bjerre P, Hagen C, Bollerslev J (1994) Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin Endocrinol (Oxf) 41:323–329 MedlineCrossRef Hansen TB, Gram J, Bjerre P, Hagen C, Bollerslev J (1994) Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin Endocrinol (Oxf) 41:323–329 MedlineCrossRef
11.
Zurück zum Zitat Brummer RJ, Lonn L, Bengtsson BA, Kvist H, Bosaeus I, Sjostrom L (1996) Comparison of different body composition models in acromegaly. Growth Regul 6:191–200 MedlinePubMed Brummer RJ, Lonn L, Bengtsson BA, Kvist H, Bosaeus I, Sjostrom L (1996) Comparison of different body composition models in acromegaly. Growth Regul 6:191–200 MedlinePubMed
12.
Zurück zum Zitat Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479 Medline. doi:10.1210/jc.83.10.3476 PubMedCrossRef Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479 Medline. doi:10.​1210/​jc.​83.​10.​3476 PubMedCrossRef
14.
Zurück zum Zitat Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E (2002) Serum leptin levels in acromegaly—a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 8:CR685–CR689 MedlinePubMed Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E (2002) Serum leptin levels in acromegaly—a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 8:CR685–CR689 MedlinePubMed
18.
Zurück zum Zitat Damjanovic SS, Petakov MS, Raicevic S et al (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154 Medline. doi:10.1210/jc.85.1.147 PubMedCrossRef Damjanovic SS, Petakov MS, Raicevic S et al (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154 Medline. doi:10.​1210/​jc.​85.​1.​147 PubMedCrossRef
19.
Zurück zum Zitat Baldelli R, Durante C, D’Amico E, Diacono F, Tamburrano G, Casanueva FF (2003) Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. J Endocrinol Invest 26:1219–1224 MedlinePubMed Baldelli R, Durante C, D’Amico E, Diacono F, Tamburrano G, Casanueva FF (2003) Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. J Endocrinol Invest 26:1219–1224 MedlinePubMed
22.
Zurück zum Zitat Paramo C, Fluiters E, de la Fuente J, Andrade A, Garcia-Mayor RV (2001) Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism 50:1117–1121 Medline. doi:10.1053/meta.2001.24882 PubMedCrossRef Paramo C, Fluiters E, de la Fuente J, Andrade A, Garcia-Mayor RV (2001) Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism 50:1117–1121 Medline. doi:10.​1053/​meta.​2001.​24882 PubMedCrossRef
23.
24.
26.
Zurück zum Zitat Lam KS, Xu A, Tan KC, Wong LC, Tiu SC, Tam S (2004) Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J Clin Endocrinol Metab 89:5448–5453 Medline. doi:10.1210/jc.2003-032023 PubMedCrossRef Lam KS, Xu A, Tan KC, Wong LC, Tiu SC, Tam S (2004) Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J Clin Endocrinol Metab 89:5448–5453 Medline. doi:10.​1210/​jc.​2003-032023 PubMedCrossRef
27.
Zurück zum Zitat Kotzmann H, Bernecker P, Hubsch P et al (1993) Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459–465 MedlinePubMedCrossRef Kotzmann H, Bernecker P, Hubsch P et al (1993) Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459–465 MedlinePubMedCrossRef
29.
Zurück zum Zitat Wiesli P, Bernays R, Brandle M, Zwimpfer C, Seiler H, Zapf J, Spinas GA, Schmid C (2005) Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin Chim Acta 352:175–181 Medline. doi:10.1016/j.cccn.2004.09.022 PubMedCrossRef Wiesli P, Bernays R, Brandle M, Zwimpfer C, Seiler H, Zapf J, Spinas GA, Schmid C (2005) Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin Chim Acta 352:175–181 Medline. doi:10.​1016/​j.​cccn.​2004.​09.​022 PubMedCrossRef
30.
Zurück zum Zitat Baum HB, Biller BM, Finkelstein JS et al (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890 MedlinePubMed Baum HB, Biller BM, Finkelstein JS et al (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890 MedlinePubMed
31.
Zurück zum Zitat Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056 Medline. doi:10.1210/jc.2003-030346 PubMedCrossRef Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056 Medline. doi:10.​1210/​jc.​2003-030346 PubMedCrossRef
32.
33.
Zurück zum Zitat Battezzati A, Benedini S, Fattorini A et al (2003) Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 284:E823–E829 MedlinePubMed Battezzati A, Benedini S, Fattorini A et al (2003) Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 284:E823–E829 MedlinePubMed
35.
36.
Zurück zum Zitat Landin K, Petruson B, Jakobsson KE, Bengtsson BA (1993) Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure. Acta Endocrinol (Copenh) 128:418–422 Medline Landin K, Petruson B, Jakobsson KE, Bengtsson BA (1993) Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure. Acta Endocrinol (Copenh) 128:418–422 Medline
38.
Zurück zum Zitat Lucidi P, Laureti S, Santoni S et al (2000) Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults. Clin Endocrinol (Oxf) 52:173–179 Medline. doi:10.1046/j.1365-2265.2000.00910.x CrossRef Lucidi P, Laureti S, Santoni S et al (2000) Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults. Clin Endocrinol (Oxf) 52:173–179 Medline. doi:10.​1046/​j.​1365-2265.​2000.​00910.​x CrossRef
39.
Zurück zum Zitat Lucidi P, Lauteri M, Laureti S et al (1998) A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 83:353–357 Medline. doi:10.1210/jc.83.2.353 PubMedCrossRef Lucidi P, Lauteri M, Laureti S et al (1998) A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 83:353–357 Medline. doi:10.​1210/​jc.​83.​2.​353 PubMedCrossRef
40.
Zurück zum Zitat Mauras N, O’Brien KO, Welch S et al (2000) Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 85:1686–1694 Medline. doi:10.1210/jc.85.4.1686 PubMedCrossRef Mauras N, O’Brien KO, Welch S et al (2000) Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 85:1686–1694 Medline. doi:10.​1210/​jc.​85.​4.​1686 PubMedCrossRef
41.
Zurück zum Zitat Nagulesparen M, Trickey R, Davies MJ, Jenkins JS (1976) Muscle changes in acromegaly. BMJ 2:914–915 MedlinePubMedCrossRef Nagulesparen M, Trickey R, Davies MJ, Jenkins JS (1976) Muscle changes in acromegaly. BMJ 2:914–915 MedlinePubMedCrossRef
42.
Zurück zum Zitat Brumback RA, Barr CE (1983) Myopathy in acromegaly. A case study. Pathol Res Pract 177:41–46 MedlinePubMed Brumback RA, Barr CE (1983) Myopathy in acromegaly. A case study. Pathol Res Pract 177:41–46 MedlinePubMed
43.
Zurück zum Zitat Pickett JB, Layzer RB, Levin SR, Scheider V, Campbell MJ, Sumner AJ (1975) Neuromuscular complications of acromegaly. Neurology 25:638–645 MedlinePubMed Pickett JB, Layzer RB, Levin SR, Scheider V, Campbell MJ, Sumner AJ (1975) Neuromuscular complications of acromegaly. Neurology 25:638–645 MedlinePubMed
44.
Zurück zum Zitat Kassem M, Mosekilde L, Eriksen EF (1994) Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 4:131–135 MedlinePubMed Kassem M, Mosekilde L, Eriksen EF (1994) Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 4:131–135 MedlinePubMed
45.
Zurück zum Zitat Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T, Chihara K (1996) Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Endocrinology 137:35–41 Medline. doi:10.1210/en.137.1.35 PubMedCrossRef Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T, Chihara K (1996) Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Endocrinology 137:35–41 Medline. doi:10.​1210/​en.​137.​1.​35 PubMedCrossRef
46.
Zurück zum Zitat Tauchmanova L, Di Somma C, Rusciano A, Lombardi G, Colao A (2007) The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest 30:35–41 MedlinePubMed Tauchmanova L, Di Somma C, Rusciano A, Lombardi G, Colao A (2007) The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest 30:35–41 MedlinePubMed
47.
Zurück zum Zitat Colao A, Pivonello R, Scarpa R, Vallone G, Ruosi C, Lombardi G (2005) The acromegalic arthropathy. J Endocrinol Invest 28:24–31 MedlinePubMed Colao A, Pivonello R, Scarpa R, Vallone G, Ruosi C, Lombardi G (2005) The acromegalic arthropathy. J Endocrinol Invest 28:24–31 MedlinePubMed
49.
Zurück zum Zitat Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B (2006) Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 24:72–78 Medline. doi:10.1007/s00774-005-0649-9 PubMedCrossRef Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B (2006) Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 24:72–78 Medline. doi:10.​1007/​s00774-005-0649-9 PubMedCrossRef
51.
52.
Zurück zum Zitat Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709–715 Medline. doi:10.1530/eje.1.02285 PubMedCrossRef Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709–715 Medline. doi:10.​1530/​eje.​1.​02285 PubMedCrossRef
53.
Zurück zum Zitat Diamond T, Nery L, Posen S (1989) Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 111:567–573 MedlinePubMed Diamond T, Nery L, Posen S (1989) Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 111:567–573 MedlinePubMed
54.
Zurück zum Zitat Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C (1996) Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1:377–382 MedlinePubMed Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C (1996) Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1:377–382 MedlinePubMed
55.
Zurück zum Zitat Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650–5655 Medline. doi:10.1210/jc.2003-030772 PubMedCrossRef Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650–5655 Medline. doi:10.​1210/​jc.​2003-030772 PubMedCrossRef
57.
Zurück zum Zitat Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T (1993) Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52:419–421 Medline. doi:10.1007/BF00571329 PubMedCrossRef Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T (1993) Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52:419–421 Medline. doi:10.​1007/​BF00571329 PubMedCrossRef
58.
Zurück zum Zitat Piovesan A, Terzolo M, Reimondo G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm Metab Res 26:234–237 MedlinePubMedCrossRef Piovesan A, Terzolo M, Reimondo G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm Metab Res 26:234–237 MedlinePubMedCrossRef
Metadaten
Titel
Alterations in body composition in acromegaly
verfasst von
Laurence Katznelson
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 2/2009
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0104-8

Weitere Artikel der Ausgabe 2/2009

Pituitary 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.